{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T08:38:51Z","timestamp":1787647131043,"version":"build-2736575974"},"reference-count":24,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T00:00:00Z","timestamp":1666224000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.eprac.2022.09.006","type":"journal-article","created":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T21:33:14Z","timestamp":1666733594000},"page":"1226-1231","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Withdrawal of Denosumab in Patients With Primary Hyperparathyroidism: A Follow-up Report of the DENOCINA Study"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0402-9903","authenticated-orcid":false,"given":"Julius Simoni","family":"Leere","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Majgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne Zacho Prie\u00df","family":"Leere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Camilla","family":"Overby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Vestergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.eprac.2022.09.006_bib1","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1210\/jc.2014-1413","article-title":"Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the fourth international workshop","volume":"99","author":"Bilezikian","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.eprac.2022.09.006_bib2","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1210\/jc.2014-1417","article-title":"Medical management of primary hyperparathyroidism: proceedings of the fourth International Workshop on the Management of Asymptomatic Primary hHyperparathyroidism","volume":"99","author":"Marcocci","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2022.09.006_bib3","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3389\/fendo.2017.00079","article-title":"Contemporary medical management of primary hyperparathyroidism : a systematic review","volume":"8","author":"Leere","year":"2017","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"10.1016\/j.eprac.2022.09.006_bib4","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s12020-011-9459-0","article-title":"Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism","volume":"39","author":"Faggiano","year":"2011","journal-title":"Endocrine"},{"issue":"5","key":"10.1016\/j.eprac.2022.09.006_bib5","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1097\/SLA.0b013e31824c5252","article-title":"Calcimimetics versus parathyroidectomy for treatment of primary hyperparathyroidism: retrospective chart analysis of a prospective database","volume":"255","author":"Keutgen","year":"2012","journal-title":"Ann Surg"},{"issue":"7","key":"10.1016\/j.eprac.2022.09.006_bib6","first-page":"655","article-title":"Cinacalcet efficacy in patients with moderately severe primary hyperparathyroidism according to the European Medicine Agency prescription labeling","volume":"35","author":"Cetani","year":"2012","journal-title":"J\u00a0Endocrinol Invest"},{"issue":"5","key":"10.1016\/j.eprac.2022.09.006_bib7","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S2213-8587(20)30063-2","article-title":"Denosumab and cinacalcet for primary hyperparathyroidism (DENOCINA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Leere","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"10.1016\/j.eprac.2022.09.006_bib8","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/jgs.15250","article-title":"Protective effect of denosumab on bone in older women with primary hyperparathyroidism","volume":"66","author":"Eller-Vainicher","year":"2018","journal-title":"J\u00a0Am Geriatr Soc"},{"issue":"3","key":"10.1016\/j.eprac.2022.09.006_bib9","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/s12020-020-02401-6","article-title":"Effects of denosumab as compared with parathyroidectomy regarding calcium, renal, and bone involvement in osteoporotic patients with primary hyperparathyroidism","volume":"69","author":"Miyaoka","year":"2020","journal-title":"Endocrine"},{"issue":"11","key":"10.1016\/j.eprac.2022.09.006_bib10","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/1759720X18805759","article-title":"New and emerging concepts in the use of denosumab for the treatment of osteoporosis","volume":"10","author":"Lewiecki","year":"2018","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"8","key":"10.1016\/j.eprac.2022.09.006_bib11","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.eprac.2022.09.006_bib12","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"10.1016\/j.eprac.2022.09.006_bib13","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1210\/jc.2014-4079","article-title":"A\u00a024-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial","volume":"100","author":"Langdahl","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.eprac.2022.09.006_bib14","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S2213-8587(18)30075-5","article-title":"Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study","volume":"6","author":"Saag","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"10.1016\/j.eprac.2022.09.006_bib15","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","volume":"361","author":"Smith","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"9992","key":"10.1016\/j.eprac.2022.09.006_bib16","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0140-6736(15)60995-3","article-title":"Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo- controlled trial","volume":"386","author":"Gnant","year":"2015","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.eprac.2022.09.006_bib17","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1007\/s00198-020-05676-7","article-title":"Hypercalcemia upon denosumab withdrawal in primary hyperparathyroidism: a case report and literature review","volume":"31","author":"Camponovo","year":"2020","journal-title":"Osteoporos Int"},{"issue":"2","key":"10.1016\/j.eprac.2022.09.006_bib18","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the placebo-controlled FREEDOM trial and its extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J\u00a0Bone Miner Res"},{"issue":"3","key":"10.1016\/j.eprac.2022.09.006_bib19","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1210\/clinem\/dgz095","article-title":"Bone mineral density after transitioning from denosumab to alendronate","volume":"105","author":"Kendler","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.eprac.2022.09.006_bib20","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1002\/jbmr.4305","article-title":"Treatment with zoledronate subsequent to denosumab in osteoporosis: a 2-year randomized study","volume":"36","author":"Solling","year":"2021","journal-title":"J\u00a0Bone Miner Res"},{"issue":"1","key":"10.1016\/j.eprac.2022.09.006_bib21","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1210\/clinem\/dgaa756","article-title":"Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS","volume":"106","author":"Tsourdi","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.eprac.2022.09.006_bib22","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1210\/jc.2006-1836","article-title":"Medical observation, compared with\u00a0parathyroidectomy, for asymptomatic primary hyperparathyroidism: a prospective, randomized trial","volume":"92","author":"Bollerslev","year":"2007","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.eprac.2022.09.006_bib23","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1046\/j.0954-6820.2003.01237.x","article-title":"Parathyroid surgery is associated with a decreased risk of hip and upper arm fractures in primary hyperparathyroidism: a controlled cohort study","volume":"255","author":"Vestergaard","year":"2004","journal-title":"J\u00a0Intern Med"},{"issue":"7261","key":"10.1016\/j.eprac.2022.09.006_bib24","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1136\/bmj.321.7261.598","article-title":"Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism","volume":"321","author":"Vestergaard","year":"2000","journal-title":"BMJ"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X22006243?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X22006243?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:13:22Z","timestamp":1761516802000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X22006243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S1530891X22006243"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2022.09.006","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Withdrawal of Denosumab in Patients With Primary Hyperparathyroidism: A Follow-up Report of the DENOCINA Study","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2022.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc. on behalf of the AACE.","name":"copyright","label":"Copyright"}]}}